Clinical Trial Update: Ingenol Mebutate Gel 0.05% in Kidney Transplant Recipients With Actinic Keratoses [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating Ingenol Mebutate Gel 0.05% for actinic keratosis in kidney transplant recipients was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Actinic Keratosis

Drugs mentioned

• Ingenol Mebutate Gel 0.05% (ingenol mebutate)

Snippet

Sponsor: Günther Hofbauer | Conditions: Actinic Keratosis | Phase 3 | Status: TERMINATED